BioNTech Shares Gain Momentum from Acquisition and Clinical Progress

BioNTech US09075V1026

Shares of BioNTech SE advanced on Wednesday, climbing approximately 2.4% to $98.50. The Mainz-based biotechnology company is receiving a dual boost from strategic corporate activity and encouraging developments in its oncology pipeline, signaling a continued shift in its market identity.

BioNTech has successfully concluded its tender offer for competitor CureVac N.V. Following the expiration of the acceptance period on December 3, 2025, BioNTech secured the required minimum acceptance threshold, with a clear majority of CureVac shareholders tendering their shares. The transaction, valued at approximately $1.25 billion, is now poised for formal completion.

This move does more than just bring CureVac's mRNA technology and Tübingen manufacturing site into the fold. It also resolves longstanding patent disputes between the two firms. For BioNTech, the deal strengthens its technological foundation while simultaneously removing a direct competitor from the landscape. This acquisition exemplifies a broader sector trend where cash-rich biotechs, bolstered by pandemic-era revenue, are engaging in strategic consolidation.

Promising Mid-Stage Data for Oncology Candidate

In a separate but concurrent development, BioNTech and its partner Bristol Myers Squibb released Phase 2 data for BNT327 (pumitamig) on December 9. The bispecific antibody, which targets PD-L1 and VEGF-A, demonstrated compelling results in patients with triple-negative breast cancer (TNBC):

• Confirmed Objective Response Rate (cORR): 61.5%
• Disease Control Rate: 92.3%
• Efficacy was observed regardless of PD-L1 status

Market analysts view these figures as highly promising, suggesting the drug is on a solid path toward pivotal Phase 3 trials. BNT327, developed in collaboration with Duality Biologics, is increasingly seen as a key asset in BioNTech's oncology portfolio, highlighting the company's research breadth beyond its core mRNA platform.

Evolving from Pandemic Leader to Diversified Biotech

The recent share price movement reflects BioNTech's ongoing strategic transformation. After hitting a low around $80 in mid-2024, the stock is now trading in the upper range of its six-month band between $95 and $115. Investors are gradually reassessing the company, placing less emphasis on its role as a COVID-19 vaccine producer and more on its potential as a diversified oncology-focused developer.

The formal integration of CureVac is anticipated in early 2026. Subsequently, focus will shift to the planned initiation of Phase 3 studies for BNT327 in the first half of 2026, targeting both lung and breast cancer indications.